{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:48Z","timestamp":1792025208498,"version":"4.4.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00284-025-04455-z","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:59:48Z","timestamp":1755694788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel Macrolide Antibiotic Nafithromycin for Tackling Emerging Resistance in Respiratory Pathogens Encountered in India"],"prefix":"10.1007","volume":"82","author":[{"given":"Swati","family":"Paliwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4821-4430","authenticated-orcid":false,"given":"Uma","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0842-5121","authenticated-orcid":false,"given":"Rajiv Kumar","family":"Tonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"4455_CR1","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/bph.13936","volume":"174","author":"GP Dinos","year":"2017","unstructured":"Dinos GP (2017) The macrolide antibiotic renaissance. Br J Pharmacol 174:2967\u20132983. https:\/\/doi.org\/10.1111\/bph.13936","journal-title":"Br J Pharmacol"},{"key":"4455_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-8579(93)90035-4","author":"JC Pech\u00e8re","year":"1993","unstructured":"Pech\u00e8re JC (1993) The use of macrolides in respiratory tract infections. Int J Antimicrob Agents. https:\/\/doi.org\/10.1016\/0924-8579(93)90035-4","journal-title":"Int J Antimicrob Agents"},{"key":"4455_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.suppl_a.1","author":"HC Neu","year":"1991","unstructured":"Neu HC (1991) The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/27.suppl_a.1","journal-title":"J Antimicrob Chemother"},{"key":"4455_CR4","unstructured":"World Health Organization (2016) Critically Important Antimicrobials for Human Medicine\u20145th Rev. WHO; Geneva, Switzerland. [(accessed on 11 August 2022)]"},{"key":"4455_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrmicro3155","volume":"12","author":"DN Wilson","year":"2014","unstructured":"Wilson DN (2014) Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol 12:35\u201348. https:\/\/doi.org\/10.1038\/nrmicro3155","journal-title":"Nat Rev Microbiol"},{"key":"4455_CR6","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/microorganisms10122316","volume":"10","author":"D Berbel","year":"2022","unstructured":"Berbel D, Gonz\u00e1lez-D\u00edaz A, L\u00f3pez de Egea G, C\u00e0mara J, Ardanuy C (2022) An overview of macrolide resistance in streptococci: prevalence. Mobile Elem Dyn Microorgan 10:2316. https:\/\/doi.org\/10.3390\/microorganisms10122316","journal-title":"Mobile Elem Dyn Microorgan"},{"key":"4455_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/jac\/dkq006","volume":"65","author":"C Ardanuy","year":"2010","unstructured":"Ardanuy C, Domenech A, Rolo D et al (2010) Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993\u20132008). J Antimicrob Chemother 65:634\u2013643. https:\/\/doi.org\/10.1093\/jac\/dkq006","journal-title":"J Antimicrob Chemother"},{"key":"4455_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/VHRM.S321025","volume":"19","author":"JW Swisher","year":"2023","unstructured":"Swisher JW, Weaver E (2023) The evolving management and treatment options for patients with pulmonary hypertension: current evidence and challenges. Vasc Health Risk Manag 19:103\u2013126. https:\/\/doi.org\/10.2147\/VHRM.S321025","journal-title":"Vasc Health Risk Manag"},{"key":"4455_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12992-024-01046-8","volume":"20","author":"B Aslam","year":"2024","unstructured":"Aslam B, Asghar R, Muzammil S et al (2024) AMR and sustainable development goals: at a crossroads. Glob Health 20:73. https:\/\/doi.org\/10.1186\/s12992-024-01046-8","journal-title":"Glob Health"},{"key":"4455_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30409-1","volume":"6","author":"India State-Level Disease Burden Initiative CRD Collaborators","year":"2018","unstructured":"India State-Level Disease Burden Initiative CRD Collaborators (2018) The burden of chronic respiratory diseases and their heterogeneity across the states of India: the global burden of disease study 1990\u20132016. Lancet Glob Health 6:e1363\u2013e1374. https:\/\/doi.org\/10.1016\/S2214-109X(18)30409-1","journal-title":"Lancet Glob Health"},{"key":"4455_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1164\/rccm.202304-0759VP","volume":"208","author":"A Mohan","year":"2023","unstructured":"Mohan A, Alupo P, Martinez FJ, Mendes RG, Zhang J, Hurst JR (2023) Respiratory health and cities. Am J Respir Crit Care Med 208:371\u2013373. https:\/\/doi.org\/10.1164\/rccm.202304-0759VP","journal-title":"Am J Respir Crit Care Med"},{"key":"4455_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab066","volume":"3","author":"B Veeraraghavan","year":"2021","unstructured":"Veeraraghavan B, Varghese R, Saigal K et al (2021) Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India. JAC-Antimicrob Resist 3:dlab066. https:\/\/doi.org\/10.1093\/jacamr\/dlab066","journal-title":"JAC-Antimicrob Resist"},{"key":"4455_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jac\/dkh178","volume":"53","author":"F Walsh","year":"2024","unstructured":"Walsh F, Carnegy F, Willcock J, Amyes S (2024) Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 53:793\u2013796. https:\/\/doi.org\/10.1093\/jac\/dkh178","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"4455_CR14","first-page":"2105","volume":"75","author":"R Ramaswamy","year":"2020","unstructured":"Ramaswamy R et al (2020) Preclinical and clinical development of nafithromycin for CABP. J Antimicrob Chemother 75(8):2105\u20132112","journal-title":"J Antimicrob Chemother"},{"key":"4455_CR15","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/cid\/ciab306","volume":"74","author":"MH Kollef","year":"2022","unstructured":"Kollef MH et al (2022) Novel antibiotics and their impact on healthcare economics. Clin Infect Dis 74:S17\u2013S22","journal-title":"Clin Infect Dis"},{"key":"4455_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1128\/JCM.39.3.1021-1024.2001","volume":"39","author":"KL O'Brien","year":"2001","unstructured":"O\u2019Brien KL, Bronsdon MA, Dagan R et al (2001) Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. J Clin Microbiol 39:1021\u20131024. https:\/\/doi.org\/10.1128\/JCM.39.3.1021-1024.2001","journal-title":"J Clin Microbiol"},{"key":"4455_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1469-0691.2006.01393.x","volume":"3","author":"BA Cunha","year":"2006","unstructured":"Cunha BA (2006) The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect 3:12\u201324. https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01393.x","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"4455_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1001\/archinte.1968.03640050038008","volume":"121","author":"JR Tillotson","year":"1968","unstructured":"Tillotson JR (1968) Hemophilus influenzae. Arch Intern Med 121(5):428. https:\/\/doi.org\/10.1001\/archinte.1968.03640050038008","journal-title":"Arch Intern Med"},{"key":"4455_CR19","unstructured":"Khattak ZE, Anjum F (2025) Haemophilus influenzae Infection. [Updated 2023 Apr 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562176\/"},{"key":"4455_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.tim.2021.04.005","volume":"29","author":"IG Gon\u00e7alves","year":"2021","unstructured":"Gon\u00e7alves IG, Sim\u00f5es LC, Sim\u00f5es M (2021) Legionella pneumophila. Trends Microbiol 29:860\u2013861. https:\/\/doi.org\/10.1016\/j.tim.2021.04.005","journal-title":"Trends Microbiol"},{"key":"4455_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.medmal.2015.01.015","volume":"45","author":"C Camp\u00e8se","year":"2015","unstructured":"Camp\u00e8se C, Descours G, Lepoutre A et al (2015) Legionnaires\u2019 disease in France. Med Mal Infect 45:65\u201371. https:\/\/doi.org\/10.1016\/j.medmal.2015.01.015","journal-title":"Med Mal Infect"},{"issue":"5","key":"4455_CR22","first-page":"532","volume":"33","author":"SS Tsai","year":"2010","unstructured":"Tsai SS et al (2010) Characteristics of Klebsiella pneumoniae bacteremia in community-acquired and nosocomial infections in diabetic patients. Chang Gung Med J 33(5):532\u2013539","journal-title":"Chang Gung Med J"},{"key":"4455_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/s0891-5520(05)70199-9","volume":"12","author":"TM File Jr","year":"1998","unstructured":"File TM Jr, Tan JS, Plouffe JF (1998) The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 12:569\u2013vii. https:\/\/doi.org\/10.1016\/s0891-5520(05)70199-9","journal-title":"Infect Dis Clin North Am"},{"key":"4455_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.rmcr.2014.03.002","volume":"12","author":"A Fujii","year":"2014","unstructured":"Fujii A, Seki M, Higashiguchi M, Tachibana I, Kumanogoh A, Tomono K (2014) Community-acquired, hospital-acquired, and healthcare-associated pneumonia caused by Pseudomonas aeruginosa. Respir Med Case Rep 12:30\u201333. https:\/\/doi.org\/10.1016\/j.rmcr.2014.03.002","journal-title":"Respir Med Case Rep"},{"key":"4455_CR25","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/antibiotics11081033","volume":"11","author":"AR Caffrey","year":"2022","unstructured":"Caffrey AR, Appaneal HJ, Liao JX, Piehl EC, Lopes V, Puzniak LA (2022) Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia. Antibiotics 11:1033. https:\/\/doi.org\/10.3390\/antibiotics11081033","journal-title":"Antibiotics"},{"key":"4455_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12879-020-05564-9","volume":"20","author":"J Hirai","year":"2022","unstructured":"Hirai J, Kinjo T, Koga T, Haranaga S, Motonaga E, Fujita J (2022) Clinical characteristics of community-acquired pneumonia due to Moraxella catarrhalis in adults: a retrospective single-centre study. BMC Infect Dis 20:821. https:\/\/doi.org\/10.1186\/s12879-020-05564-9","journal-title":"BMC Infect Dis"},{"key":"4455_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf810","author":"D Hoban","year":"2002","unstructured":"Hoban D, Felmingham D (2002) The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother. https:\/\/doi.org\/10.1093\/jac\/dkf810","journal-title":"J Antimicrob Chemother"},{"key":"4455_CR28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3201\/eid1104.040822","volume":"11","author":"KA Beynon","year":"2005","unstructured":"Beynon KA, Young SA, Laing RT, Harrison TG, Anderson TP, Murdoch DR (2005) Bordetella pertussis in adult pneumonia patients. Emerg Infect Dis 11:639\u2013641. https:\/\/doi.org\/10.3201\/eid1104.040822","journal-title":"Emerg Infect Dis"},{"key":"4455_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1378\/chest.80.2.220","volume":"80","author":"PA Herbert","year":"1981","unstructured":"Herbert PA, Bayer AS (1981) Fungal pneumonia (part 4): invasive pulmonary aspergillosis. Chest 80:220\u2013225. https:\/\/doi.org\/10.1378\/chest.80.2.220","journal-title":"Chest"},{"key":"4455_CR30","unstructured":"A. L. Association, \u201cPneumonia Symptoms and Diagnosis,\u201d https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/pneumonia\/symptoms-and-diagnosis."},{"key":"4455_CR31","unstructured":"A. L. Association, \u201cPneumonia,\u201d https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/pneumonia."},{"key":"4455_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/jmv.20045","volume":"72","author":"C L\u00f3pez-Palomo","year":"2004","unstructured":"L\u00f3pez-Palomo C, Mart\u00edn-Zamorano M, Ben\u00edtez E et al (2004) Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 72:517\u2013524. https:\/\/doi.org\/10.1002\/jmv.20045","journal-title":"J Med Virol"},{"key":"4455_CR33","unstructured":"\u201cTypes of Pneumonia,\u201d https:\/\/www.webmd.com\/lung\/pneumonia-types."},{"key":"4455_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-43044-9.00155-2","volume":"1196\u20131201","author":"J Nowicki","year":"2020","unstructured":"Nowicki J, Murray MT (2020) Bronchitis and Pneumonia. Textbook Natural Med 1196\u20131201:e1. https:\/\/doi.org\/10.1016\/B978-0-323-43044-9.00155-2","journal-title":"Textbook Natural Med"},{"issue":"4","key":"4455_CR35","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1148\/rg.2017160110","volume":"37","author":"HLP Orlowski","year":"2017","unstructured":"Orlowski HLP et al (2017) Imaging spectrum of invasive fungal and fungal-like infections. Radiographics 37(4):1119\u20131134. https:\/\/doi.org\/10.1148\/rg.2017160110","journal-title":"Radiographics"},{"key":"4455_CR36","doi-asserted-by":"publisher","DOI":"10.4103\/0975-7406.155808","author":"S Dharmic","year":"2015","unstructured":"Dharmic S, Nair S, Harish M (2015) An unusual cause of fungal pneumonia. J Pharm Bioallied Sci. https:\/\/doi.org\/10.4103\/0975-7406.155808","journal-title":"J Pharm Bioallied Sci"},{"key":"4455_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","volume":"183","author":"AH Limper","year":"2011","unstructured":"Limper AH, Knox KS, Sarosi GA et al (2011) An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96\u2013128","journal-title":"Am J Respir Crit Care Med"},{"key":"4455_CR38","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3389\/fimmu.2019.01524","volume":"10","author":"Z Li","year":"2019","unstructured":"Li Z, Lu G, Meng G (2019) Pathogenic fungal infection in the lung. Front Immunol 10:1524. https:\/\/doi.org\/10.3389\/fimmu.2019.01524","journal-title":"Front Immunol"},{"key":"4455_CR39","unstructured":"Medications for Pneumonia. Drugs.com. https:\/\/www.drugs.com\/condition\/pneumonia.html"},{"key":"4455_CR40","unstructured":"Teflaro.https:\/\/www.drugs.com\/teflaro.html#:~:text=Teflaro%20is%20a%20cephalosporin%20(SEF,and%2012%20days%20postnatal%20age)."},{"key":"4455_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011825.pub2","author":"MP Hansen","year":"2019","unstructured":"Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM et al (2019) Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD011825.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4455_CR42","unstructured":"US Food and Drug Administration (2013) FDA Drug Safety Communication: azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. Silver Spring, MD: US Food and Drug Administration."},{"key":"4455_CR43","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/14651858.CD011825.pub2","volume":"66","author":"WA Ray","year":"2012","unstructured":"Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 66:1881\u201390. https:\/\/doi.org\/10.1002\/14651858.CD011825.pub2","journal-title":"N Engl J Med"},{"key":"4455_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/cea.12468","volume":"45","author":"R Mirakian","year":"2015","unstructured":"Mirakian R, Leech SC, Krishna MT, Richter AG, Huber PAJ, Farooque S et al (2015) Management of allergy to penicillins and other beta-lactams. Clin Exp Allergy 45:300\u201327. https:\/\/doi.org\/10.1111\/cea.12468","journal-title":"Clin Exp Allergy"},{"key":"4455_CR45","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1503\/cmaj.140848","volume":"187","author":"M Gillies","year":"2015","unstructured":"Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P et al (2015) Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. CMAJ 187:E21-31. https:\/\/doi.org\/10.1503\/cmaj.140848","journal-title":"CMAJ"},{"key":"4455_CR46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(18)32218-9","volume":"393","author":"KG Blumenthal","year":"2019","unstructured":"Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ (2019) Antibiotic allergy. Lancet 393:183\u2013198. https:\/\/doi.org\/10.1016\/S0140-6736(18)32218-9","journal-title":"Lancet"},{"key":"4455_CR47","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ (2005) Safety of doxycycline and minocycline: a systematic review. Clin Ther 27:1329\u20131342. https:\/\/doi.org\/10.1016\/j.clinthera.2005.09.005","journal-title":"Clin Ther"},{"key":"4455_CR48","doi-asserted-by":"publisher","first-page":"180","DOI":"10.5152\/tjg.2014.5415","volume":"25","author":"MS Da\u011f","year":"2014","unstructured":"Da\u011f MS, \u00d6zt\u00fcrk ZA, Ak\u0131n I, Tutar E, \u00c7\u0131kman \u00d6, G\u00fcl\u015fen MT (2014) Drug-induced esophageal ulcers: case series and the review of the literature. Turk J Gastroenterol 25:180\u20134. https:\/\/doi.org\/10.5152\/tjg.2014.5415","journal-title":"Turk J Gastroenterol"},{"key":"4455_CR49","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1001\/archderm.1997.03890460044005","volume":"133","author":"LE Shapiro","year":"1997","unstructured":"Shapiro LE, Knowles SR, Shear NH (1997) Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 133:1224\u201330","journal-title":"Arch Dermatol"},{"key":"4455_CR50","unstructured":"AIDSinfo (2018) Vancomycin hydrochloride. 6. Adverse reactions. Rockville, MD: US Department of Health and Human Services. Available from: https:\/\/aidsinfo.nih.gov\/drugs\/550\/vancomycinhydrochloride\/186\/professional#nlm34084-4."},{"key":"4455_CR51","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7150\/ijms.30739","volume":"16","author":"C Teng","year":"2019","unstructured":"Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR (2019) Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system. Int J Med Sci 16:630\u20135. https:\/\/doi.org\/10.7150\/ijms.30739","journal-title":"Int J Med Sci"},{"issue":"10","key":"4455_CR52","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00044-024-03281-5","volume":"33","author":"S Bhawsar","year":"2024","unstructured":"Bhawsar S, Tadiparthi R, Kayastha AK et al (2024) Nafithromycin (MIQNAF\u00ae): ultramodern lactone ketolide designed to treat community acquired bacterial pneumonia (CABP). Med Chem Res 33(10):1715\u20131733. https:\/\/doi.org\/10.1007\/s00044-024-03281-5","journal-title":"Med Chem Res"},{"key":"4455_CR53","doi-asserted-by":"publisher","first-page":"dlab066","DOI":"10.1093\/jacamr\/dlab066","volume":"3","author":"B Veeraraghavan","year":"2021","unstructured":"Veeraraghavan B, Varghese R, Saigal K, Balasubramanian S, Bai PSP, Lal YB, Neeravi A, Baskar P, Anandhan K, Kumar CPG, Jayaraman Y, Nag VL, Baveja S (2021) Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India. JAC Antimicrob Resist. 3:dlab066. https:\/\/doi.org\/10.1093\/jacamr\/dlab066","journal-title":"JAC Antimicrob Resist."},{"key":"4455_CR54","first-page":"2583","volume":"3","author":"SA Ahmed","year":"2025","unstructured":"Ahmed SA, Mustafa SA (2025) India launches Nafithromycin: a game-changer in the fight against antimicrobial resistance. Acad Int J Multi Res 3:2583\u2013973","journal-title":"Acad Int J Multi Res"},{"key":"4455_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/antibiotics5030029","volume":"5","author":"D Jeli\u0107","year":"2016","unstructured":"Jeli\u0107 D, Antolovi\u0107 R (2016) From erythromycin to azithromycin and new potential ribosome-binding antimicrobials. Antibiotics (Basel) 5:29. https:\/\/doi.org\/10.3390\/antibiotics5030029","journal-title":"Antibiotics (Basel)"},{"key":"4455_CR56","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1128\/AAC.39.9.2141","volume":"39","author":"WS Champney","year":"1995","unstructured":"Champney WS, Burdine R (1995) Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother 39:2141\u20134. https:\/\/doi.org\/10.1128\/AAC.39.9.2141","journal-title":"Antimicrob Agents Chemother"},{"key":"4455_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111615","author":"G Muteeb","year":"2023","unstructured":"Muteeb G, Rehman MT, Shahwan M, Aatif M (2023) Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16111615","journal-title":"Pharmaceuticals (Basel)"},{"key":"4455_CR58","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3390\/molecules28041762","volume":"28","author":"Z Shi","year":"2023","unstructured":"Shi Z, Zhang J, Tian L, Xin L, Liang C, Ren X, Li M (2023) A comprehensive overview of the antibiotics approved in the last two decades: retrospects and prospects. Molecules 28:1762. https:\/\/doi.org\/10.3390\/molecules28041762","journal-title":"Molecules"},{"key":"4455_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s44259-023-00016-1","volume":"1","author":"D Saxena","year":"2023","unstructured":"Saxena D, Maitra R, Bormon R et al (2023) Tackling the outer membrane: facilitating compound entry into gram-negative bacterial pathogens. NPJ Antimicrob Resist 1:17. https:\/\/doi.org\/10.1038\/s44259-023-00016-1","journal-title":"NPJ Antimicrob Resist"},{"key":"4455_CR60","unstructured":"Pophale H, Gupta M, Llorens L, Iwanowski P, Gutte R, et al. A Phase III, Randomized, Double-Blind Controlled Trial Evaluating the Efficacy and Safety of a 3-Day Once-Daily Regimen of Oral Nafithromycin in Comparison to Oral Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults."},{"issue":"3","key":"4455_CR61","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1021\/tx300050f","volume":"25","author":"N Penner","year":"2012","unstructured":"Penner N, Xu L, Prakash C (2012) Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25(3):513\u2013531. https:\/\/doi.org\/10.1021\/tx300050f","journal-title":"Chem Res Toxicol"},{"key":"4455_CR62","unstructured":"ClinicalTrials.gov. Phase II Study of Oral Nafithromycin in CABP. https:\/\/www.clinicaltrials.gov\/study\/NCT02903836"},{"issue":"8","key":"4455_CR63","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","volume":"76","author":"MS Butler","year":"2023","unstructured":"Butler MS, Henderson IR, Capon RJ, Blaskovich MAT (2023) Antibiotics in the clinical pipeline as of December 2022. J Antibiot 76(8):431\u2013473. https:\/\/doi.org\/10.1038\/s41429-023-00629-8","journal-title":"J Antibiot"},{"key":"4455_CR64","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/147323000102900408","volume":"29","author":"T Schaberg","year":"2001","unstructured":"Schaberg T, Ballin I, Huchon G, Bassaris H (2001) A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 29:314\u2013328. https:\/\/doi.org\/10.1177\/147323000102900408","journal-title":"J Int Med Res"},{"key":"4455_CR65","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1261\/rna.071720.119","volume":"26","author":"MA Rubio Gomez","year":"2020","unstructured":"Rubio Gomez MA, Ibba M (2020) Aminoacyl-tRNA synthetases. RNA 26:910\u201336. https:\/\/doi.org\/10.1261\/rna.071720.119","journal-title":"RNA"},{"key":"4455_CR66","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.tibs.2018.06.011","volume":"43","author":"N V\u00e1zquez-Laslop","year":"2018","unstructured":"V\u00e1zquez-Laslop N, Mankin AS (2018) How macrolide antibiotics work. Trends Biochem Sci 43:668\u201384. https:\/\/doi.org\/10.1016\/j.tibs.2018.06.011","journal-title":"Trends Biochem Sci"},{"key":"4455_CR67","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1749-6632.2011.06315.x","volume":"1241","author":"K Kannan","year":"2011","unstructured":"Kannan K, Mankin AS (2011) Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action. Ann N Y Acad Sci 1241:33\u201347. https:\/\/doi.org\/10.1111\/j.1749-6632.2011.06315.x","journal-title":"Ann N Y Acad Sci"},{"key":"4455_CR68","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1046\/j.1365-2958.1999.01202.x","volume":"31","author":"LH Hansen","year":"1999","unstructured":"Hansen LH, Mauvais P, Douthwaite S (1999) The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 31:623\u201331. https:\/\/doi.org\/10.1046\/j.1365-2958.1999.01202.x","journal-title":"Mol Microbiol"},{"key":"4455_CR69","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1128\/AAC.48.10.3677-3683.2004","volume":"48","author":"GW Novotny","year":"2004","unstructured":"Novotny GW, Jakobsen L, Andersen NM, Poehlsgaard J, Douthwaite S (2004) Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA. Antimicrob Agents Chemother 48:3677\u201383. https:\/\/doi.org\/10.1128\/AAC.48.10.3677-3683.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"4455_CR70","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1038\/s41467-023-39653-5","volume":"14","author":"CW Chen","year":"2023","unstructured":"Chen CW, Leimer N, Syroegin EA, Dunand C, Bulman ZP, Lewis K et al (2023) Structural insights into the mechanism of overcoming Erm-mediated resistance by macrolides acting together with hygromycin-A. Nat Commun 14:4196. https:\/\/doi.org\/10.1038\/s41467-023-39653-5","journal-title":"Nat Commun"},{"key":"4455_CR71","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/antibiotics12121715","volume":"12","author":"D Paul","year":"2023","unstructured":"Paul D, Chawla M, Ahrodia T, Narendrakumar L, Das B (2023) Antibiotic potentiation as a promising strategy to combat macrolide resistance in bacterial pathogens. Antibiotics (Basel) 12:1715. https:\/\/doi.org\/10.3390\/antibiotics12121715","journal-title":"Antibiotics (Basel)"},{"key":"4455_CR72","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1007\/s11696-023-02725-3","volume":"77","author":"S Bhavsar","year":"2023","unstructured":"Bhavsar S, Tadiparthi R, Gupta S et al (2023) Design and development of efficient synthetic strategies for the chiral synthesis of novel ketolide antibiotic, nafithromycin (WCK 4873). Chem Pap 77:3629\u20133640. https:\/\/doi.org\/10.1007\/s11696-023-02725-3","journal-title":"Chem Pap"},{"key":"4455_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab066","volume":"3","author":"B Veeraraghavan","year":"2021","unstructured":"Veeraraghavan B, Varghese R, Saigal K et al (2021) Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India. JAC-Antimicrob Resist 3:dlab066. https:\/\/doi.org\/10.1093\/jacamr\/dlab066","journal-title":"JAC-Antimicrob Resist"},{"key":"4455_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2022.100757","volume":"5","author":"S Bhavsar","year":"2022","unstructured":"Bhavsar S, Ravikumar T, Gupta S, Pawar S, Dabhade S, Kayastha AK et al (2022) WCK 4873 (INN: nafithromycin): structure\u2013activity relationship (SAR) identifying a novel lactone ketolide with activity against Streptococcus pneumoniae (SPN) and Streptococcus pyogenes (SPY). Results Chem 5:100757. https:\/\/doi.org\/10.1016\/j.rechem.2022.100757","journal-title":"Results Chem"},{"key":"4455_CR75","unstructured":"DrugBank (n.d.) Nafithromycin (DB16246). https:\/\/go.drugbank.com\/drugs\/DB16246"},{"key":"4455_CR76","doi-asserted-by":"publisher","first-page":"dlab066","DOI":"10.1093\/jacamr\/dlab066","volume":"3","author":"B Veeraraghavan","year":"2021","unstructured":"Veeraraghavan B, Varghese R, Saigal K, Balasubramanian S, Bai PSP, Lal YB et al (2021) Activity of novel lactone ketolide nafithromycin against multicentric invasive and non-invasive pneumococcal isolates collected in India. JAC Antimicrob Resist 3:dlab066. https:\/\/doi.org\/10.1093\/jacamr\/dlab066","journal-title":"JAC Antimicrob Resist"},{"key":"4455_CR77","doi-asserted-by":"crossref","unstructured":"Cill\u00f3niz C, Garcia-Vidal C, Ceccato A, Torres A (2018) Antimicrobial resistance among Streptococcus pneumoniae. In: Antimicrobial Resistance in the 21st Century. Springer, Cham","DOI":"10.1007\/978-3-319-78538-7_2"},{"key":"4455_CR78","volume-title":"In vitro activity of WCK 4873 (nafithromycin) against resistant subsets of Streptococcus pneumoniae from a global surveillance program (2014)","author":"DJ Farrell","year":"2016","unstructured":"Farrell DJ, Sader HS, Rhomberg PR, Flamm RK, Jones RN (2016) In vitro activity of WCK 4873 (nafithromycin) against resistant subsets of Streptococcus pneumoniae from a global surveillance program (2014). ASM Microbe, American Society for Microbiology, Presented at"},{"key":"4455_CR79","unstructured":"Centers for Disease Control and Prevention (n.d.) About Chlamydia pneumoniae. https:\/\/www.cdc.gov\/cpneumoniae\/about\/index.html"},{"key":"4455_CR80","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2147\/JEP.S259286","volume":"12","author":"J Sellar\u00e8s-Nadal","year":"2020","unstructured":"Sellar\u00e8s-Nadal J, Burgos J, Falc\u00f3 V, Almirante B (2020) Investigational and experimental drugs for community-acquired pneumonia: the current evidence. J Exp Pharmacol 12:529\u2013538. https:\/\/doi.org\/10.2147\/JEP.S259286","journal-title":"J Exp Pharmacol"},{"key":"4455_CR81","doi-asserted-by":"publisher","unstructured":"Hammerschlag MR, Kohlhoff SA, Gaydos CA (2015) Chlamydia pneumoniae. In: Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, 8th edn. Elsevier, Philadelphia, pp 2174\u20132182. https:\/\/doi.org\/10.1016\/B978-1-4557-4801-3.00184-3","DOI":"10.1016\/B978-1-4557-4801-3.00184-3"},{"key":"4455_CR82","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00585-21","volume":"65","author":"S Kohlhoff","year":"2021","unstructured":"Kohlhoff S, Hammerschlag MR (2021) In vitro activity of nafithromycin (WCK 4873) against Chlamydia pneumoniae. Antimicrob Agents Chemother 65:e00585\u201321. https:\/\/doi.org\/10.1128\/AAC.00585-21","journal-title":"Antimicrob Agents Chemother"},{"key":"4455_CR83","unstructured":"Taylor TA, Unakal CG (2025) Staphylococcus aureus Infection. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)"},{"key":"4455_CR84","unstructured":"Wikipedia contributors (2024) Staphylococcus. Wikipedia. https:\/\/en.wikipedia.org\/w\/index.php?title=Staphylococcus&oldid=1254052119"},{"key":"4455_CR85","doi-asserted-by":"publisher","DOI":"10.5492\/wjccm.v13.i1.87459","volume":"13","author":"B Jatteppanavar","year":"2024","unstructured":"Jatteppanavar B, Choudhury A, Panda PK, Bairwa M (2024) Community-acquired multidrug-resistant pneumonia, bacteraemia, and infective endocarditis: a case report. World J Crit Care Med 13:87459. https:\/\/doi.org\/10.5492\/wjccm.v13.i1.87459","journal-title":"World J Crit Care Med"},{"key":"4455_CR86","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01253-19","volume":"63","author":"P Iwanowski","year":"2019","unstructured":"Iwanowski P, Bhatia A, Gupta M et al (2019) Safety, tolerability and pharmacokinetics of oral nafithromycin (WCK4873) after single or multiple doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 63:e01253\u201319. https:\/\/doi.org\/10.1128\/AAC.01253-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4455_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac103","volume":"4","author":"M Zhou","year":"2022","unstructured":"Zhou M, Wu L, Kang W, Li Y, Zhang G, Zhang J et al (2022) In vitro activity of lactone ketolide nafithromycin (WCK 4873) against Streptococcus pneumoniae isolates enriched with macrolide-resistance phenotype collected from mainland China. JAC Antimicrob Resist 4:dlac103. https:\/\/doi.org\/10.1093\/jacamr\/dlac103","journal-title":"JAC Antimicrob Resist"},{"key":"4455_CR88","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1128\/JCM.00972-17","volume":"55","author":"MA Hackel","year":"2017","unstructured":"Hackel MA, Karlowsky JA, Dressel D, Sahm DF (2017) Determination of disk diffusion and MIC quality control ranges for nafithromycin (WCK 4873), a new lactone-ketolide. J Clin Microbiol 55:3021\u20133027. https:\/\/doi.org\/10.1128\/JCM.00972-17","journal-title":"J Clin Microbiol"},{"key":"4455_CR89","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/pharmaceutics12090846","volume":"12","author":"M Deodhar","year":"2020","unstructured":"Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V (2020) Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics 12:846. https:\/\/doi.org\/10.3390\/pharmaceutics12090846","journal-title":"Pharmaceutics"},{"key":"4455_CR90","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/00498254.2020.1839983","volume":"51","author":"R Chavan","year":"2021","unstructured":"Chavan R, Zope V, Chavan N, Patil K, Yeole R, Bhagwat S et al (2021) Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic. Xenobiotica 51:251\u2013261. https:\/\/doi.org\/10.1080\/00498254.2020.1839983","journal-title":"Xenobiotica"},{"key":"4455_CR91","unstructured":"Wikipedia contributors (2024) Lower respiratory tract infection. Wikipedia. https:\/\/en.wikipedia.org\/w\/index.php?title=Lower_respiratory_tract_infection&oldid=1265720045"},{"key":"4455_CR92","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01096-17","volume":"61","author":"KA Rodvold","year":"2017","unstructured":"Rodvold KA, Gotfried MH, Chugh R, Gupta M, Friedland HD, Bhatia A (2017) Comparison of plasma and intrapulmonary concentrations of nafithromycin (WCK 4873) in healthy adult subjects. Antimicrob Agents Chemother 61:e01096\u201317. https:\/\/doi.org\/10.1128\/AAC.01096-17","journal-title":"Antimicrob Agents Chemother"},{"key":"4455_CR93","unstructured":"American Lung Association (n.d.) Pneumonia: Symptoms and diagnosis. https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/pneumonia\/symptoms-and-diagnosis"},{"key":"4455_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155049","volume":"129","author":"J Trivedi","year":"2020","unstructured":"Trivedi J, Shaikh J, Chavan N, Thorve D, Chaudhary B, Karade A et al (2020) Pretreatment of nafithromycin attenuates inflammatory response in murine lipopolysaccharide induced acute lung injury. Cytokine 129:155049. https:\/\/doi.org\/10.1016\/j.cyto.2020.155049","journal-title":"Cytokine"},{"key":"4455_CR95","unstructured":"David S, Kim PY (2025) Drug Trials. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546595\/"},{"key":"4455_CR96","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01253-19","volume":"63","author":"P Iwanowski","year":"2019","unstructured":"Iwanowski P, Bhatia A, Gupta M, Patel A, Chavan R, Yeole R et al (2019) Safety, tolerability and pharmacokinetics of oral nafithromycin (WCK4873) after single or multiple doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 63:e01253\u201319. https:\/\/doi.org\/10.1128\/AAC.01253-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4455_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2021.104889","volume":"122","author":"M Nandanwar","year":"2021","unstructured":"Nandanwar M, Chavan R, Kansagara A, Patel MA, Patel A, Yeole R et al (2021) Preclinical safety evaluation of nafithromycin (WCK 4873) with emphasis on liver safety in rat and dog. Regul Toxicol Pharmacol 122:104889. https:\/\/doi.org\/10.1016\/j.yrtph.2021.104889","journal-title":"Regul Toxicol Pharmacol"},{"key":"4455_CR98","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.4155\/bio-2019-0153","volume":"11","author":"KR Patil","year":"2019","unstructured":"Patil KR, Yeole RD, Zwart M, Pruim P (2019) Simultaneous determination of novel ketolide antibiotic nafithromycin and its major metabolite in human plasma using liquid chromatography tandem mass spectrometry. Bioanalysis 11:1767\u20131776. https:\/\/doi.org\/10.4155\/bio-2019-0153","journal-title":"Bioanalysis"},{"key":"4455_CR99","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fmb-2022-0027","volume":"17","author":"A Singh","year":"2022","unstructured":"Singh A et al (2022) Nafithromycin \u2013 a novel lactone ketolide with activity against drug-resistant respiratory pathogens. Future Microbiol 17:563\u2013576","journal-title":"Future Microbiol"},{"key":"4455_CR100","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/healthcare11131946","volume":"11","author":"MA Salam","year":"2023","unstructured":"Salam MA, Al-Amin MY, Salam MT et al (2023) Antimicrobial resistance: a growing serious threat for global public health. Healthcare (Basel) 11:1946. https:\/\/doi.org\/10.3390\/healthcare11131946","journal-title":"Healthcare (Basel)"},{"key":"4455_CR101","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejpb.2019.12.008","volume":"147","author":"M Mir","year":"2020","unstructured":"Mir M, Permana AD, Ahmed N, Khan GM, Rehman AU, Donnelly RF (2020) Enhancement in site-specific delivery of carvacrol for potential treatment of infected wounds using infection responsive nanoparticles loaded into dissolving microneedles: a proof of concept study. Eur J Pharm Biopharm 147:57\u201368","journal-title":"Eur J Pharm Biopharm"},{"key":"4455_CR102","volume":"2","author":"AD Permana","year":"2020","unstructured":"Permana AD, Mir M, Utomo E, Donnelly RF (2020) Bacterially sensitive nanoparticle-based dissolving microneedles of doxycycline for enhanced treatment of bacterial biofilm skin infection: a proof of concept study. Int J Pharm X 2:100047","journal-title":"Int J Pharm X"},{"key":"4455_CR103","unstructured":"Control A (n.d.) Global governance to tackle antimicrobial resistance: The way forward. Accessed 4 Apr 2025."}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04455-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-025-04455-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-025-04455-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T06:51:11Z","timestamp":1758264671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-025-04455-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":103,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4455"],"URL":"https:\/\/doi.org\/10.1007\/s00284-025-04455-z","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"465"}}